Edward Clark profile picture

Contact Information

Edward Clark, MD MSc FRCPC
613-798-5555 x82569

Edward Clark

Associate Scientist, Acute Care Research
Ottawa Hospital Research Institute
Dr. Shiv L. Jindal Chair for the Prevention of Kidney Disease
Ottawa Hospital Research Institute
Associate Professor, Department of Medicine
University of Ottawa
Cross Appointed Faculty, School of Epidemiology and Public Health
University of Ottawa
Nephrologist and Medical Director for Critical Care Nephrology
The Ottawa Hospital

Research Interests

Primary Focus:
  • Acute Kidney Injury
  • Critical Care Nephrology
  • Renal Replacement Therapy

Other Interests:

  • Vascular Access for Acute RRT
  • Living Kidney Donation

Brief Biography

Edward Clark is a Staff Nephrologist, Associate Professor and Medical Director of Critical Care Nephrology at The Ottawa Hospital and the University of Ottawa. He is also cross-appointed to the School of Epidemiology and Public Health and an Associate Scientist in the Clinical Epidemiology Program of the Ottawa Hospital Research Institute.
His medical education has been at Queen's University (Kingston, ON) and McGill University (Montreal, QC) with a Masters in Epidemiology from the University of Ottawa. He is dual-trained and certified in Nephrology and Critical Care Medicine with a clinical and academic focus on Acute Kidney Injury and Renal Replacement Therapy.

Selected Publications

  • Clark EG, James MT, Hiremath S, Sood MM, Wald R, Garg AX, Silver SA, Tan Z, van Walraven C: Predictive Models for Kidney Recovery and Death in Patients Continuing Dialysis as Outpatients after Starting In Hospital. Clin J Am Soc Nephrol, 2023
  • Chan RJ, Helmeczi W, Canney M, Clark EG: Management of Intermittent Hemodialysis in the Critically Ill Patient. Clin J Am Soc Nephrol, 18: 245-255, 2023
  • Clark EG, McIntyre L, Watpool I, Kong JWY, Ramsay T, Sabri E, Canney M, Hundemer GL, Brown PA, Sood MM, Hiremath S. Intravenous albumin for the prevention of hemodynamic instability during sustained low-efficiency dialysis: a randomized controlled feasibility trial (The SAFER-SLED Study). Ann Intensive Care 2021; 11: 174.
  • Hryciw N, Joannidis M, Hiremath S, Callum J, Clark EG. Intravenous Albumin for Mitigating Hypotension and Augmenting Ultrafiltration during Kidney Replacement Therapy. Clinical journal of the American Society of Nephrology : CJASN 2021; 16: 820-828

Diseases, conditions and populations of interest

Research and clinical approaches